GlassScriptPhysician profile
Abbas H Mansour
NPI 1326092156
$31,842.51
in general payments reported to CMS, 2019-2025
43 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $2,663 · 2021: $2,913 · 2022: $3,313 · 2023: $3,349 · 2024: $3,013 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,750 · Travel and Lodging: $704 · Education: $195 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,064.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,750.00 |
| Travel and Lodging | $703.99 |
| Education | $195.37 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14,526.26 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $5,444.08 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,028.59 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $1,156.27 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $976.05 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $945.70 | 2019-2025 | Dupixent |
| Amgen INC. | $738.80 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $728.65 | 2020-2025 | Glassia |
| Genzyme Corporation | $713.76 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $617.82 | 2020-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $464.69 | 2019-2025 | Opsumit, Uptravi |
| Electromed, INC. | $453.27 | 2021-2025 | Smartvest |
| Verona Pharma, INC. | $392.07 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $377.19 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $275.01 | 2019-2023 | Xolair |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $232.09 | 2020-2025 | Vest Therapy Und |
| Covis Pharma Gmbh | $212.87 | 2021-2022 | |
| United Therapeutics Corporation | $211.84 | 2021-2022 | |
| Axsome Therapeutics, INC. | $148.81 | 2024-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $119.77 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $111.76 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $95.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $85.51 | 2019-2022 | |
| Circassia INC. | $79.89 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Baxter Healthcare | $69.48 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $64.94 | 2025 | Zepbound, Mounjaro |
| Mallinckrodt Enterprises LLC | $64.66 | 2019 | |
| Advanced Respiratory, INC | $62.72 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $62.14 | 2023-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $52.16 | 2019-2020 | |
| Harmony Biosciences LLC | $49.81 | 2023-2025 | Wakix |
| Csl Behring | $45.56 | 2020-2025 | Hizentra |
| Daiichi Sankyo INC. | $39.77 | 2020 | |
| Jazz Pharmaceuticals INC. | $23.08 | 2020 | |
| Ani Pharmaceuticals, INC. | $20.23 | 2022 | |
| Merck Sharp & Dohme LLC | $19.35 | 2022 | |
| Abbvie INC. | $14.99 | 2022 | |
| Tactile Systems Technology INC | $14.39 | 2024 | Flexitouch Plus, Entre Plus |
| Snap Diagnostics LLC | $13.14 | 2024 | Snap Diagnostics Study |
| Pulmonx Corporation | $10.98 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.